ALAMEDA, Calif., Dec. 3, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, announced today that President and Chief Executive Officer Kenneth Chahine, Ph.D., J.D., will participate in a panel presentation entitled "Reinventing the Neurology Armamentarium" on Wednesday, December 10, 2008, from 8:00-8:55 a.m. EST as part of the 2008 RBC Capital Markets Healthcare Conference being held at the Westin Times Square Hotel in New York City.
RBC will conduct a live audio webcast of the presentation. To access the webcast over the Internet, please go to www.avigen.com. Rebroadcast of the presentation will be available shortly after the conclusion of the session and can be accessed over the internet at www.avigen.com.
About Avigen
Avigen is a biopharmaceutical company focused on developing and commercializing unique small molecule therapeutics to treat serious neurological disorders, including neuropathic pain and opioid addiction and withdrawal. Avigen's strategy is to identify, qualify, and develop each of the candidates in its product pipeline, including strategic clinical development in collaboration with development partners. Avigen continues to look for opportunities to add candidates to its portfolio through a combination of internal research, acquisitions and in-licensing. Avigen is currently developing AV411 for neuropathic pain, as well as opioid withdrawal and addiction in collaboration with NIDA. Additionally, the company is advancing AV513, a novel therapy for the treatment of multiple bleeding disorders, including hemophilia A and B, toward clinical trials. For more information about Avigen, consult the company's website at www.avigen.com.
The Avigen, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2981
Statement under the Private Securities Litigation Reform Act
This press release contains forward-looking statements, which include, among others, statements relating to Avigen's intention of adding value through the development for each of the candidates in its product pipeline, including strategic clinical development in collaboration with development partners, and looking for opportunities to add candidates to its portfolio through a combination of internal research, acquisitions, and in-licensing. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. In addition, there are many other risks and uncertainties inherent in the development of drug products. Other risks and uncertainties relating to Avigen are detailed in reports filed by Avigen with the Securities and Exchange Commission, including Avigen's Annual Report on Form 10-K for the year ended December 31, 2007, under the caption "Risk Factors" in Item 1A of Part I of that report which was filed with the SEC on March 17, 2008 and Avigen's quarterly report on Form 10-Q for the period ended September 30, 2008, under the caption "Risks Related to Our Business" in Item 2 of Part I of that report, which was filed with the SEC on November 10, 2008.